918博天堂(中华区)官方网站

Huaota is pleased to announce that HB002.1M ophthalmic injection project independently developed by the company obtained IND issued by the National Medical Products Administration for 3 new indications. To date, HB002.1M ophthalmic injection has a total of 4 indications (wet age-related macular degeneration, macular edema secondary to branch retinal vein occlusion, macular edema secondary to central retinal vein occlusion, and diabetic macular edema) approved by NMPA for clinical trials. A total of RMB 87.6 million yuan has been invested in research and development of this product.

The first indication of HB002.1M ophthalmic injection, wet age-related macular degeneration, has progressed to Phase II clinical trials. HB002.1M is a recombinant fusion protein targeting vascular endothelial growth factor (VEGF), which is intended for the treatment of the above four indications. VEGF is recognized as the most rapid and effective vascular permeability and angiogenesis factor. The pathogenesis of the above four indications are all related to the abnormal expression of VEGF. The use of recombinant proteins or monoclonal antibodies targeting VEGF can effectively treat the above diseases.